Status:
COMPLETED
ZAP, US. Zomig for Appropriate for Primary Care
Lead Sponsor:
AstraZeneca
Conditions:
Migraine
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™ (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in treating migraine over a...
Eligibility Criteria
Inclusion
- Have an established diagnose of migraine as with an age at onset of less than 50 years
- Have experienced an average of at least 1 migraine headache per month in the previous three months
- Be able to differentiate between migraine and non-migraine headaches
Exclusion
- Use of any triptan within the last 12 months or use of MAO-A inhibitors, methysergide or methylergonovine in the 2 weeks before entering the study.
- History of basilar, ophthalmoplegic or hemiplegic migraine headache or any potentially serious neurological condition that is associated with headache
- History, symptoms, or significant risk factors for ischaemic heart or other cardiovascular disease, including coronary vasospasm, cardiac accessory conduction pathways or arrhythmias or uncontrolled hypertension.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00637286
Start Date
July 1 2004
End Date
May 1 2005
Last Update
April 6 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.